Internal Medicine, Rheumatology · Boston, MA
NPI
1932308244
Since 2007
Specialty
Internal Medicine, Rheumatology
Code 207RR0500X
Group practices
2
Medicare group memberships
Hospitals
2
Hospital affiliations
55 Fruit St
Boston, MA, 02114
Phone (617) 726-7938
Groups this clinician bills Medicare through
Medicare paid, 2024
$1.1M
75,183 services
Medicare patients, 2024
1,451
Average age 71
Drug cost, 2024
$3.5M
7,004 prescriptions
Company payments, 2025
$274
From 5 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Mark C Fisher was code J0897 (injection, denosumab, 1 mg), 19,620 times for 210 patients. In total Mark C Fisher billed 75,183 services in 103 codes, and Medicare paid $1.1M.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2013-11-22.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J0897 Injection, denosumab, 1 mg | Office | 19,620 | 210 | $20.26 | $397K |
| J1010 Injection, methylprednisolone acetate, 1 mg | Office | 1,200 | 16 | $0.10 | $115 |
| 99214 Office E&M - Established | Office | 721 | 417 | $91.04 | $66K |
| 77080 Standard X-ray | Office | 675 | 672 | $39.69 | $27K |
| 36415 Venipuncture Blood Collection | Office | 606 | 388 | $8.65 | $5,242 |
| 80053 Clinical Chemistry | Office | 454 | 284 | $10.30 | $4,674 |
| 85025 Blood Count | Office | 449 | 285 | $7.57 | $3,399 |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 415 | 285 | $12.67 | $5,258 |
| J3489 Injection, zoledronic acid, 1 mg | Office | 385 | 76 | $4.58 | $1,765 |
| 85652 Clinical Chemistry | Office | 338 | 245 | $2.63 | $889 |
| 77081 Standard X-ray | Office | 320 | 319 | $32.26 | $10K |
| 96401 Chemotherapy Administration | Office | 315 | 186 | $57.50 | $18K |
| 86140 Clinical Chemistry | Office | 294 | 212 | $5.05 | $1,485 |
| 99204 Office E&M - New | Office | 146 | 146 | $122.87 | $18K |
| 96413 Chemotherapy Administration | Office | 136 | 34 | $106.62 | $14K |
By year: 2022 $566K for 29,806 services; 2023 $609K for 29,806 services; 2024 $1.1M for 75,183 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 36415 Venipuncture Blood Collection | 606 | 388 | $8.65 | $5,242 |
| 80053 Clinical Chemistry | 454 | 284 | $10.30 | $4,674 |
| 85025 Blood Count | 449 | 285 | $7.57 | $3,399 |
| 85652 Clinical Chemistry | 338 | 245 | $2.63 | $889 |
| 86140 Clinical Chemistry | 294 | 212 | $5.05 | $1,485 |
| 81015 Clinical Chemistry | 93 | 76 | $2.96 | $276 |
| 84550 Clinical Chemistry | 52 | 34 | $4.29 | $223 |
| 86708 Immunoassay | 43 | 42 | $11.91 | $512 |
| 82310 Clinical Chemistry | 40 | 32 | $5.06 | $202 |
| G0499 Hepatitis b screening in non-pregnant, high risk individual includes hepatitis b surface antigen (hbsag), antibodies to hbsag (anti-hbs) and antibodies to hepatitis b core antigen (anti-hbc), and is followed by a neutralizing confirmatory test, when perfor | 38 | 38 | $27.70 | $1,053 |
Medicare prescription drug claims, 2024
In 2024, the drug Mark C Fisher prescribed most often to Medicare patients was Hydroxychloroquine Sulfate, with 966 prescriptions and refills. In total Mark C Fisher wrote 7,004 Medicare prescriptions that cost $3.5M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Hydroxychloroquine Sulfate Generic | 966 | 1,175 | 201 | $24K |
| Gabapentin Generic | 913 | 1,146 | 214 | $13K |
| Prednisone Generic | 670 | 745 | 180 | $4,352 |
| Duloxetine Hcl Generic | 563 | 849 | 153 | $7,247 |
| Pregabalin Generic | 369 | 425 | 86 | $14K |
| Celecoxib Generic | 300 | 352 | 68 | $9,672 |
| Zonisamide Generic | 259 | 484 | 85 | $4,128 |
| Meloxicam Generic | 256 | 295 | 56 | $879 |
| Nortriptyline Hcl Generic | 232 | 351 | 65 | $2,439 |
| Methotrexate Methotrexate Sodium | 231 | 350 | 55 | $3,835 |
| Alendronate Sodium Generic | 178 | 300 | 51 | $1,251 |
| Leflunomide Generic | 164 | 287 | 48 | $6,293 |
| Sulfasalazine Generic | 117 | 175 | 34 | $3,097 |
| Tizanidine Hcl Generic | 113 | 175 | 43 | $1,507 |
| Allopurinol Generic | 88 | 175 | 24 | $757 |
Brand drugs: - claims; generic drugs: 6,353 claims; opioid claims: 77.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Mark C Fisher $274 ($274 in general payments such as food, travel and fees) from 5 companies. The largest payer was Abbvie Inc. with $187.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.